Abivax: over 1,000 patients enrolled in the ABTECT study

(CercleFinance.com) - Abivax announces that it has reached an important milestone in the ABTECT phase 3 clinical trial evaluating obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), with enrolment having reached 1003 patients out of 1224.


The biotech company notes that patient recruitment is expected to be finalized in Q2 2025, with first results from the eight-week induction trial expected in Q3 of this year.

Maintenance data at 44 weeks remain expected in Q2 2026, and if positive, the U.S. New Drug Application (NDA) is expected to be submitted in H2 2026.

Copyright (c) 2025 CercleFinance.com. All rights reserved.